Abstract
Objective: In individuals without radiographic knee osteoarthritis (OA), we investigated whether magnetic resonance imaging (MRI)–defined knee OA at baseline was associated with incident radiographic and symptomatic disease during up to 11 years of follow-up. Methods: Osteoarthritis Initiative participants without tibiofemoral radiographic knee OA at baseline were assessed for MRI-based tibiofemoral cartilage damage, osteophyte presence, bone marrow lesions, and meniscal damage/extrusion. We defined MRI knee OA using alternative, reported definitions (Def A and Def B). Kellgren–Lawrence (KL) grade, joint space narrowing (JSN), and frequent knee symptoms (Sx) were assessed at baseline, 1-, 2-, 3-, 4-, 6-, 8-, and 10/11-year follow-up visits. Incident tibiofemoral radiographic knee OA (outcome) was defined as (1) KL ≥2, (2) KL ≥2 and JSN, or (3) KL ≥2 and Sx. Adjusted Cox proportional hazards regression models examined associations of baseline MRI-defined knee OA (Def A and Def B) with incident outcomes during up to 11 years of follow-up. Results: Among 1,621 participants (mean ± SD age 58.8 ± 9.0 years, mean ± SD body mass index 27.2 ± 4.5 kg/m2, 59.5% women), 17% had MRI-defined knee OA by Def A and 24% by Def B. Baseline MRI-defined knee OA was associated with incident KL ≥2 (odds ratio 2.94 [95% confidence interval (95% CI) 2.34–3.68] for Def A and 2.44 [95% CI 1.97–3.03] for Def B). However, a substantial proportion of individuals with baseline MRI-defined knee OA did not develop incident KL ≥2 during follow-up (59% for Def A and 64% for Def B). Findings were similar for the other two outcomes. Conclusion: Current MRI definitions of knee OA do not adequately identify knees that will develop radiographic and symptomatic disease.
Original language | English (US) |
---|---|
Pages (from-to) | 140-150 |
Number of pages | 11 |
Journal | Arthritis and Rheumatology |
Volume | 77 |
Issue number | 2 |
DOIs | |
State | Published - Feb 2025 |
Funding
This article was prepared using an Osteoarthritis Initiative (OAI) public\u2010use data set, and its contents do not necessarily reflect the opinions or views of the OAI Study Investigators, the NIH, or the private funding partners of the OAI. The OAI is a public\u2013private partnership between the NIH (contracts N01\u2010AR\u20102\u20102258, N01\u2010AR\u20102\u20102259, N01\u2010AR\u20102\u20102260, N01\u2010AR\u20102\u20102261, and N01\u2010AR\u20102\u20102262) and private funding partners (Merck Research Laboratories, Novartis Pharmaceuticals, GlaxoSmithKline, and Pfizer, Inc.) and is conducted by the OAI Study Investigators. Private sector funding for the OAI is managed by the Foundation for the NIH. Supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH (grant P30\u2010AR\u2010072579).
ASJC Scopus subject areas
- Immunology and Allergy
- Rheumatology
- Immunology